"A new study reports Eli Lilly's Alzheimer's drug slowed cognitive and functional decline for people with early stages of the disease.
The data, published Monday in the Journal of the American Medical Association, found the experimental drug donanemab slowed decline by 35% compared to a placebo group based on a measure of daily activities such as driving, managing finances and talking about current events. Researchers also shared the data at the Alzheimer's Association International Conference in Amsterdam."
